Google+ Facebook Twitter Twitter

Stopping Parkinson's disease

It may be possible to stop the progression of Parkinson’s disease with a drug usually used for type 2 diabetes.

The news follows a clinical trial involving 60 patients.

Current drugs help manage the symptoms, but do not prevent brain cells dying.

But exenatide, which is from a class of compounds originally isolated from lizard venom, could slow or stop progress.

Researchers gave exenatide to 31 people with moderate Parkinson’s disease over 48 weeks. They injected the drug every day, except the day before assessments. 

While 29 people with a similar level of disease did the same with a placebo.

Eight weeks after the conclusion of the trial, the research team assessed all the volunteers’ symptoms. 

Those who had received the placebo had deteriorated by an average of three points on a 200-point scale – a typical rate of decline for people with Parkinson’s.

Those who had taken exenatide showed an average improvement of one point, putting them four points
ahead of the placebo group. 

Brain scans also showed that those taking the drug had less degeneration. 

However, these effects were subtle – they didn’t perform better in cognitive tests, and there was no visible improvement in their day-to-day symptoms.

The findings of the trials are published in The Lancet.


Related Articles

Preventing allergic reactions

Researchers have discovered a new mechanism in which an antibody can prevent allergic reactions in a broad range of patients.

No antibiotics for sore throats

Doctors should not prescribe antibiotics for most people with sore throats, say new guidelines. While most sore throats are caused by viral infections, research suggests antibiotics are prescribed in 60% of cases.

The enzyme that defines colon cancer

Researchers have identified an enzyme that is absent in healthy colon tissue but abundant in colon cancer cells. It appears to drive the conversion of normal tissue into cancer by attaching sugar molecules, or glycans, to proteins in the cell.

Repurposed Zika drug

A drug used to treat hepatitis C effectively protected and rescued neural cells infected by the Zika virus. The results were consistent across cell cultures and mouse models. It also blocked transmission of the virus to mouse foetuses, the research found.